Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution
Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution
复制标题
DOI：
10.1245/s10434-011-1703-6
复制
发表时间：
2011-10-01
影响因子：
3.7
通讯作者：
Figarella-Branger, Dominique
中科院分区：
文献类型：
--
作者：
Metellus, Philippe;Nanni-Metellus, Isabelle;Figarella-Branger, Dominique
背景。癌症干细胞被认为是负责肿瘤发展的致瘤细胞群的代表。CD133抗原已被描述为恶性脑肿瘤中假定的干细胞标记物，可以识别胶质母细胞瘤亚群中的此类致瘤性群体。迄今为止，CD133在原发性胶质母细胞瘤中的表达与患者预后的关系尚不明确。为了解决这个问题，我们在胶质母细胞瘤患者队列中研究了CD133 mRNA表达与患者预后之间的关系。材料与方法。在48例连续接受替莫唑胺放化疗的原发性胶质母细胞瘤患者中，采用实时定量定量pcr技术评估了CD133干细胞抗原mRNA的定量表达。在多变量生存分析中，高CD133 mRNA表达是与肿瘤切除程度（P = 0.012）和MGMT甲基化状态（P = 0.002）无关的不良无进展和总生存率的显著预后因素（P = 0.007）。患者年龄也是总生存率的独立预测指标（P = 0.037）。根据CD133 mRNA的联合表达和MGMT状态将患者分为3组，预后均相同。这些发现为CD133干细胞抗原mRNA表达的测定确实影响GBM患者的生存提供了确凿的证据。
Background. Cancer stem cells are thought to represent the population of tumorigenic cells responsible for tumor development. The CD133 antigen has been described as a putative stem cell marker in malignant brain tumor that could identify such a tumorigenic population in a subset of glioblastoma. To date, the correlation between CD133 expression in primary glioblastoma and patient prognosis is not clearly established. To address this question we investigated the relationship between CD133 mRNA expression and patient outcome in a glioblastoma patient cohort.Materials and Methods. The quantitative expression of CD133 stem cell antigen mRNA using real-time QRT-PCR was assessed in a cohort of 48 consecutive primary glioblastoma patients treated by chemoradiation with temozolomide.Results. On multivariate survival analysis, high CD133 mRNA expression was a significant (P = 0.007) prognostic factor for adverse progression-free and overall survival independent of extent of resection (P = 0.012) and MGMT methylation status (P = 0.002). Patient age was also an independent prognosticator of overall survival (P = 0.037). Furthermore, according to the conjoined expression of CD133 mRNA and MGMT status, the patients were categorized into 3 groups with homogenous prognosis.Conclusions. These findings constitute conclusive evidence that the measurement of the mRNA expression of CD133 stem cell antigen actually impacts the survival of GBM patients.